PharmAla's lead product is a scalable 40mg dosage of Methylenedioxymethamphetamine, formulated for use by psychiatrists and psychotherapists in the treatment of Post-Traumatic Stress Disorder. It is under investigation by over 25 different clinical trials at institutions such as Johns Hopkins, UCLA, Yale and many others. Institutional clients include the US Military through the Defence Health Agency, and the US Department of Veterans Affairs. Commercially available in Canada and Australia.